• news.cision.com/
  • PolarCool/
  • PolarCool AB (publ) presents improved results from the pilot study with SHL and HockeyAllsvenskan

PolarCool AB (publ) presents improved results from the pilot study with SHL and HockeyAllsvenskan

Report this content

In collaboration with the Swedish Hockey League (SHL) and HockeyAllsvenskan, PolarCool conducted a study during the past three seasons, wherein PolarCap® System has been evaluated for the treatment of concussion. A total of 12 teams participated in the study; the intervention group has used the PolarCap® System and the control group has consisted of players who have not received the treatment.

The purpose of the clinical study has been to measure symptom relief, in order to examine how quickly the player progresses through a mandatory rehab program until return to play. The program is a rehabilitation process with progressively increased activity that lasts for at least 6 days, where the last step involves full participation in training or match (so-called Return To Play).

In April 2019, PolarCool published results from, till then, reported cases in the pilot study. On August 16, PolarCool announced that additional obtained data further strengthened the preliminary results showing significant benefits of cooling with the PolarCap® System. This led to the principal investigator deciding on the intention to make a scientific publication.

Now all the additional data from the previous season have been obtained and analyzed, and the results show even more clearly that cooling with PolarCap® System has been advantageous in the treatment of concussion. A total of 80 cases were reported in the study. The median time for return to play for the intervention group, treated with PolarCap® System, was 7 days and for those not treated 12 days. The results are statistically significant (p < 0.001).

In addition, more players in the control group (12 of 51; 24%) were absent from games longer than 3 weeks, compared to the intervention group (2 of 29; 7%). These results are also statistically significant (p = 0.028).

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on September 6, 2019. 

For more information

Iman Ziai – CEO                                          
+46 - 733 -99 23 17                                                                              
E-mail: iman.ziai@polarcool.se

Om PolarCool AB (publ)

PolarCool AB (publ) är ett medicinteknikföretag som utvecklar, marknadsför och säljer produkter inom idrottsmedicin. Bolaget fokuserar på behandling av hjärnskakning och upprepade huvudkollisioner. PolarCool AB (publ) har sitt säte i Lund. Aktien är noterad på Spotlight Stock Market. 



Documents & Links